Current and future drug therapies for claudication

Vascular Medicine

Volumn 2, Issue 3, 1997, Pages 257-268

  Hiatt, William R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Intermittent claudication; Peripheral arterial disease; Pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; ANGIOGENIC FACTOR; ANTITHROMBOCYTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BERAPROST; BUPHENINE; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; NIFEDIPINE; PAPAVERINE; PENTOXIFYLLINE; PLACEBO; PROPIONYLCARNITINE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; TICLOPIDINE; VASCULOTROPIN; VASODILATOR AGENT;

ARTERY DISEASE; CLAUDICATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; EXERCISE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEG ISCHEMIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION;

EID: 0030830516     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863x9700200316     Document Type: Conference Paper

References (54)

1. Hiatt WR, Marshall JA, Baxter J et al. Diagnostic methods for peripheral arterial disease in the San Luis Valley Diabetes Study. J Clin Epidemiol 1990; 43: 597-606.
2. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985, 71: 510-15.
3. Olsen PS, Gustafsen J, Rasmussen L, Lorentzen JE. Long-term results after arterial surgery for arteriosclerosis of the lower limbs in young adults. Eur J Vasc Surg 1988; 2: 15-18.
4. Stergachis A, Sheingold S, Luce BR, Psaty BM, Revicki DA. Medical care and cost outcomes after pentoxifylline treatment for peripheral arterial disease. Arch Intern Med 1992; 152: 1220-24.
5. Tunis SR, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med 1991; 325: 556-62.
6. Jelnes R, Gaardsting O, Hougaard-Jensen K, Baekgaard N, Tonnesen KH. Fate in intermittent claudication: outcome and risk factors. Br Med J 1986; 293: 1137-40.
7. Singer A, Rob C. The fate of the claudicator. Br Med J 1960: 633-36
8. Juergens JL, Barker NW, Hines EA. Arteriosclerosis obliterans: a review of 520 cases with special reference to pathogenic and prognostic factors. Circulation 1960; 21: 188-95.
9. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. Diabetes 1989; 38: 504-509.
10. Beach KW, Strandness DE. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes 1980; 29: 882-88.
11. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1991; 211: 249-56.
12. Orchard TJ, Strandness DE, Cavanagh PR et al. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop. Circulation 1993; 88: 819-28.
13. Pomrehn P, Duncan B, Weissfeld L et al. The association of dyslipoproteinemia with symptoms and signs of peripheral arterial disease. The lipids research clinics program prevalence study. Circulation 1986; 73 (suppl I): I-100-I-107.
14. Drexel H, Steurer J, Muntwyler J et al. Predictors of the presence and extent of peripheral arterial occlusive disease. Circulation 1996; 94 (suppl II): II-199-II-205.
15. Valentine JR, Graybum PA, Vega GL, Grudy M. Lp(a) lipoprotein is an independent, discriminating risk factor for premature atherosclerosis among white men. Arch Intern Med 1994; 154: 801-806.
16. Olsson AG, Ruhn G, Erikson U. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study. J Intern Med 1990; 227: 381-90.
17. Blankenhom DH, Azen SP, Crawford DW et al. Effects of colestipolniacin therapy on human femoral atherosclerosis. Circulation 1991; 83: 438-47.
18. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 1985; 33: 13-18.
19. Krupski WC. The peripheral vascular consequences of smoking. Ann Vasc Surg 1991; 5: 291-304.
20. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. β blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. Br Med J 1991; 303: 1100-104.
21. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
22. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-31.
23. Goldhaber SZ, Manson JE, Stampfer MJ et al. Low-dose aspirin and subsequent peripheral arterial surgery in the physicians' health study. Lancet 1992; 340: 143-45.
24. Hess H, Deichsel G, Mietaschk A. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; i: 415-19.
25. Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study J Intern Med 1990; 227: 301-308.
26. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
27. Coffman JD. Vasodilator drugs in peripheral vascular disease N Engl J Med 1979, 300: 713-17.
28. Spence JD, Arnold JMO, Munoz CE et al. Angiotensin-converting enzyme inhibition with cliazapril does not improve blood flow, walking time, or plasma lipids in patients with intermittent claudication. J Vasc Med Biol 1993; 4: 23-28.
29. Bagger JP, Helligsoe P, Randsbaek F, Kimose HH, Jensen BS. Effect of verapamil in intermittent claudication. A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. Circulation 1997; 95: 411-14.
30. Porter JM, Cutler BS, Lee BY et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104: 66-72.
31. Lindgarde F, Jelnes R, Bjorkman H et al. Conservative drug treatment m patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 1989; 80: 1549-56.
32. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study J Am Coll Cardiol 1995; 26: 1411-16.
33. Goto V, D'Alessandro L, Grattarola G et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs Exp Clin Res 1992; 18: 29-36.
34. Balsano F, Coccheri S, Libretti A et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med 1989; 114: 84-91.
35. Lievre M, Azoulay S, Lion L, Mornd S, Girre JP, Boissel JP. A dose-effect study of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 1996; 27: 788-93.
36. Money SR. Effects of cilostazol on walking distances, quality of life, and resting ankle brachial indices in patients with intermittent claudication secondary to peripheral arterial disease. Presented at the Annual Meeting of the Society for Vascular Surgery and the North American Chapter of the International Society for Cardiovascular Surgery, Boston, Massachusetts, 1-4 June 1997 [abstract].
37. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988; 39: 802-11.
38. Willerson JT. Inhibitors of platelet glycoprotein IIb/IIIa receptors. Will they be useful when given chronically? Circulation 1996; 94: 866-68.
39. Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-20
40. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 1996; 155: 1053-59.
41. PACK Claudication Substudy Investigators. Randomized placebo controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. Circulation 1989; 80: 1544-18.
42. Bieber LL. Carnitine. Ann Rev Biochem 1988; 57: 261-83.
43. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992; 73: 346-53.
44. Brevetti G, Chiariello M, Ferulano G et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77: 767-73.
45. Brevetti G, Perna S, Sabba C et al. Superiority of L-propionyl carnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992; 13: 251-55.
46. Brevetti G, Perna S, Sabba C, Martone VD, Di Lorio A, Barletta G. Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 1997; 79: 777-80.
47. Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994; 90: 818-22.
48. 1 prodrug, in patients with intermittent claudication. Circulation 1997; 95: 2298-302.
49. Okuda Y, Kimura Y, Yamashita K. Cilostazol. Cardiovasc Drug Rev 1993; 11: 451-65.
50. Takeshita S, Zheng LP, Brogi E et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662-70.
51. Tsurumi Y, Takeshita S, Chen D et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996, 94: 3281-90.
52. Picano E, Testa R, Pogliani M et al. Increase of walking capacity after acute aminophylline administration in intermittent claudication. Angiology 1989; 40: 1035-39.
53. Cook NS, Rudin M, Pally C, Blarer S, Quast U. Effects of the potassium channel openers SDZ-PCO 400 and cromakalim in an in vivo rat model of occlusive arterial disease assessed by 31P-NMR spectroscopy. J Vasc Med Biol 1993; 4: 14-22.
54. Guldager B, Jelnes R, Jorgensen SJ et al. EDTA treatment of intermittent claudication - a double blind, placebo-controlled study. J Intern Med 1992; 231; 261-67.